08.04.16
Teva
2Q Revenues: $5.0 billion (+1%)
2Q Earnings: $242 million (-55%)
YTD Revenues: $9.8 billion (-1%)
YTD Earnings: $875 million (-11%)
Comments: Specialty Medicines sales were $2.3 billion, up 9% with higher revenues in all core therapeutic areas. U.S. specialty medicines revenues were $1.8 billion, up 9%. European specialty medicines revenues were $414 million, up 10%, and ROW revenues were $85 million, down 6%. Generic sales were $2.3 billion in the quarter, down 7% with a decline in sales of aripiprazole (Abilify), esomeprazole (Nexium) and budesonide (Pulmicort) due to loss of exclusivity in the U.S. API sales to third parties were $207 million, up 13%. R&D expenses (excluding equity compensation expenses and purchase of in-process R&D) in the quarter was $370 million, up 4%.
2Q Revenues: $5.0 billion (+1%)
2Q Earnings: $242 million (-55%)
YTD Revenues: $9.8 billion (-1%)
YTD Earnings: $875 million (-11%)
Comments: Specialty Medicines sales were $2.3 billion, up 9% with higher revenues in all core therapeutic areas. U.S. specialty medicines revenues were $1.8 billion, up 9%. European specialty medicines revenues were $414 million, up 10%, and ROW revenues were $85 million, down 6%. Generic sales were $2.3 billion in the quarter, down 7% with a decline in sales of aripiprazole (Abilify), esomeprazole (Nexium) and budesonide (Pulmicort) due to loss of exclusivity in the U.S. API sales to third parties were $207 million, up 13%. R&D expenses (excluding equity compensation expenses and purchase of in-process R&D) in the quarter was $370 million, up 4%.